- September 6, 2023NEW YORK, September 6, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- August 17, 2023– Unblinded Interim Biomarker Analysis Expected in the Fall of 2023 – – Full Data Readout Expected in April 2025…
- August 3, 2023– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective…
- August 1, 2023NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- July 27, 2023– Webcast to be Held at 8:00 am ET on August 3, 2023 – NEW YORK, July 27, 2023 – Immunic,…
- June 29, 2023NEW YORK, June 29, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- May 30, 2023NEW YORK, May 30, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…
- May 17, 2023– Preclinical Data Published in the Peer-Reviewed Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator –…
- May 11, 2023– Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach…
- May 9, 2023– Webcast to be Held at 8:00 am ET on May 11, 2023 – NEW YORK, May 9, 2023 – Immunic,…
